CERo Therapeutics Holdings Overview
Valuation check: CERO's ROE is 416.3%, above the sector sector average of 11.64%.
Get informed when a big investor buys or sells
+ Follow416.30%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CERO is 416.3%. That is above the sector sector average of 11.64%. Investors often review this figure alongside CERo Therapeutics Holdings's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, CERO currently prints 416.3% for ROE, while the sector average sits near 11.64%. That is roughly 3477.5% above the sector mean. Large gaps often invite a closer look at CERo Therapeutics Holdings's growth, margins, and balance sheet.
Return on Equity shows how effectively CERo Therapeutics Holdings converts resources into returns. At 416.3%, CERO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CERO's ROE (416.3%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
